首页>
外国专利>
COMBINATION THERAPY FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
COMBINATION THERAPY FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
展开▼
机译：联合疗法治疗复发/耐药CD22 + B细胞急性淋巴白血病的成人患者
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to use of combination therapy with an anti-CD22 antibody, such as epratuzumab or hRFB4, and another therapeutic agent for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Preferably the therapeutic agent is a chemotherapeutic agent, more preferably vincristine and/or dexamethasone. The combination therapy can induce complete responses in resistant/refractory ALL and may unexpectedly provide an improved MRD, indicative of long-term disease-free survival, in older human ALL patients.
展开▼
